Objective: to analyze the structural state of the central area of the retina in diabetic macular edema in the background anti-VEGF therapy.Methods. The study included 38patients (40eyes) with diabetic macular edema. All patients received anti-VEGF-ranibizumab therapy at a dose of 0.05ml. The results were analyzed after three intravitreal injections with 1month interval. We assessed visual acuity, morphological and anatomical structure of the macular area, the sensitivity of the retina and macular pigment optical densityResults. Analyzing optical density of the macular pigment we revealed a significant increase of all parameters in 73% of patients after the therapy. The average value of the optical density before treatment was at 0.102±0.01du, on the background of anti-VEGF-therapy this figure went up to 0.213±0.01 (p<0.05). According to the optical coherence to-mography average retinal thickness before treatment made 404.62±15.23μm, after the treatment – 300.91±6.43μm (р<0,05). When comparing data of optical coherence tomography and macular pigment optical density we revealed more pronounced decrease in the macular pigment optical density in the area of the retinal edema and a significant increase in the basic parameters on the background of the therapy.Conclusion. Anti-VEGF-therapy significantly improves visual acuity, the recovery profile of macular edema and reduces the zone in patients with diabetic macular edema.
diabetic macular edema, macular pigment optical density, ranibizumab
1. BikbovMM, FayzrakhmanovRR, ZaynullinRМ (2014). Syndrome of vitreomacular traction [Sindrom vitreomakulyarnoy traktsii]. Kataraktal’naya i refraktsionnaya khirurgiya, (2), 15-17.
2. BikbovMM, FayzrakhmanovRR, YarmukhametovaAL, ZaynullinRM (2015). Anatomic mapping of diabetic macular edema according to optical coherence tomography during anti-VEGF therapy [Anatomicheskoe kartirovanie diabeticheskogo makulyarnogo oteka po dannym opticheskoy kogerentnoy tomografii pri provedenii antivazoproliferativnoy terapii]. Sovremennye tekhnologii v oftal’mologii, (1), 31-33
3. ShishkinMM, YuldashevaNM, AntonyukSV, YusupovAF, MuzaffarovUR (2011). Differentiated approach to the prescription of angiogenetic inhibitors for diabetic macular edema [Differentsirovannyy podkhod k naznacheniyu ingibitorov angiogeneza pri diabeticheskom makulyarnom oteke]. Vestnik Natsional’nogo mediko-khirurgicheskogo tsentra im. N.I.Pirogova, (3), 24-28.
4. BosciaF (2010). Current approaches to the management of diabetic retinopathy and diabetic macular oedema. Drugs, 70(16), 2171-2200.
5. BrownDM, NguyenQD, MarcusDM, BoyerDS,PatelS, FeinerL, SchlottmannPG, RundleAC, ZhangJ, RubioRG, AdamisAP, EhrlichJS, HopkinsJJ, RISERIDE Research Group (2013). Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase IIItrials: RISE and RIDE. Ophthalmology, 120(10), 2013-2022
6. CheungN, MitchellP, WongTY (2010). Diabetic retinopathy. Lancet, 376(9735), 124-136.
7. CiullaTA, AmadorAG, ZinmanB (2003). Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care, 26(9), 2653-2664.
8. DingJ, WongTY (2012). Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr. Diab. Rep., 12(4), 346-354
9. KlaassenI, Van NoordenCJ, SchlingemannRO(2013). Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog. Retin. Eye Res., (34), 19-48.
10. LardenoyeCW, ProbstK, DeLintPJ, RothovaA (2000). Photoreceptor function in eyes with macular edema. Invest. Ophthalmol. Vis. Sci., 41(12), 4048-4053.
11. McBainVA, ForresterJV, LoisN (2008). Fundus autofluorescence in the diagnosis of cystoid macular oedema. Br. J. Ophthalmol., 92(7), 946-949.
12. NguyenQD, BrownDM, MarcusDM, BoyerDS, PatelS, FeinerL, GibsonA, SyJ, RundleAC, HopkinsJJ, RubioRG, EhrlichJS, RISE RIDE Research Group (2012). Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology, 119(4), 789-801.
13. ShawJE, SicreeRA, ZimmetPZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res. Clin. Pract., 87(1), 4-14.
14. ZhangX, BaoS, HamblyBD, GilliesMC (2009) Vascular endothelial growth factor-A: a multifunctional molecular player in diabetic retinopathy. Int. J. Biochem. Cell Biol., 41(12), 2368-2371
